戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  in the treatment of side effects induced by antilymphocyte antibodies.
2 eived either ganciclovir or acyclovir during antilymphocyte antibody administration.
3 tomegalovirus (CMV) and who are treated with antilymphocyte antibody (ALA) therapy have a high rate o
4 ells (BMC) can prolong allograft survival in antilymphocyte antibody- (ALA) treated recipients.
5 e were fewer episodes of rejection requiring antilymphocyte antibodies and fewer study discontinuatio
6                                              Antilymphocyte antibodies are widely used to prevent and
7 d previously received at least one course of antilymphocyte antibody as rejection therapy.
8        Fewer CsA-NL patients (5.9%) required antilymphocyte antibody (ATG or OKT-3) therapy for rejec
9 atal grafts could be supported by monoclonal antilymphocyte antibodies, B10.A(5R) recipients were imm
10                                   The use of antilymphocyte antibodies for induction therapy or for t
11                                   The use of antilymphocyte antibodies for the treatment of rejection
12             Induction immunosuppression with antilymphocyte antibodies has not been shown to improve
13 , whereas results of studies with monoclonal antilymphocyte antibodies have been disappointing.
14 an adult study population; (2) assessment of antilymphocyte antibodies in the immediate posttransplan
15 renal allografts who did and did not receive antilymphocyte antibodies in the perioperative period we
16 have not shown that the perioperative use of antilymphocyte antibodies (induction therapy) improves s
17                  The majority of steroid and antilymphocyte antibody (OKT3 or ATGAM) unresponsive rej
18                                   The use of antilymphocyte antibody or cyclosporine on day 0/1 decre
19 tors, antitumor necrosis factor-alpha drugs, antilymphocyte antibodies, or chemotherapeutic agents),
20 tithymocyte globulins (AThG) are a subset of antilymphocyte antibody preparations derived from the se
21 pients, and significantly reduces the use of antilymphocyte antibody preparations.
22 ulin (IVIG) in the treatment of steroid- and antilymphocyte antibody-resistant rejection in renal tra
23          IVIG rescue therapy for steroid- or antilymphocyte antibody-resistant rejection is associate
24  therapy rescued three of four patients with antilymphocyte antibody-resistant rejection.
25 ere treated with IVIG to reverse steroid- or antilymphocyte antibody-resistant rejection.
26       Alemtuzumab (Campath-1H) is a powerful antilymphocyte antibody that produces profound and long-
27  were fewer CsA-NL patients (6.9%) requiring antilymphocyte antibody therapy for rejection than in th
28  reduced number of CsA-NL patients requiring antilymphocyte antibody therapy for rejection, fewer Int
29                                              Antilymphocyte antibody therapy was not used to treat re
30 ravenous ganciclovir for the duration of any antilymphocyte antibody therapy, in our kidney and simul
31 primary CMV infection and in those receiving antilymphocyte antibody therapy.
32                      Furthermore, additional antilymphocyte antibody treatment was required to revers
33                                              Antilymphocyte antibody was required in eight (13%) pati

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。